References - CAPLYTA® (lumateperone) Skip to Main Content For US Residents Only Visit US Healthcare Professionals Site Download Brochure Important Safety Information Prescribing Information Medication Guide Other Indications Important Safety Information Prescribing Information Medication Guide Cost & Savings Close Menu About Bipolar Depression About CAPLYTA CAPLYTA Results Taking CAPLYTA Common Side Effects Tools & Resources Helpful Tools Additional Resources Real Patient Videos Ask About CAPLYTA Cost & Savings Cost & Savings Download Brochure For US Residents only Visit US Healthcare Professionals Site Other Indications About Bipolar Depression About CAPLYTA CAPLYTA Results Taking CAPLYTA Common Side Effects Tools & Resources Helpful Tools Additional Resources Real Patient Videos Ask About CAPLYTA Cost & Savings Cost & Savings References Bipolar disorder. Mayo Clinic. February 16, 2021. Accessed January 31, 2025. https://www.mayoclinic.org/diseases-conditions/bipolar-disorder/symptoms-causes/syc-20355955. Bipolar Disorder. National Institute of Mental Health. Accessed January 31, 2025. https://www.nimh.nih.gov/health/statistics/bipolar-disorder. CAPLYTA Prescribing Information. Centers for Medicare and Medicaid Services. Medicare Prescription Drug Benefit Manual: Chapter 13-Premium and cost-sharing subsidies for low-income individuals. Updated July 29, 2011. Accessed January 31, 2025. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/ Downloads /Chapter13.pdf. Culpepper, L. The Diagnosis and Treatment of Bipolar Disorder: Decision-Making in Primary Care. Prim Care Companion J Clin Psychiatry . 2014;16(3):1-10. Accessed January 31, 2025. Diagnostic and Statistical Manual of Mental Disorders. DSM‑5. 5th ed., American Psychiatric Association. 2013;5:125‑170. Accessed January 31, 2025. eHealth Medicare. Low-income Subsidy-Medicare Extra Help Program. Accessed January 31, 2025. https://www.ehealthmedicare.com/ medicare -part-d-articles/low-income-subsidy- medicare -extra-help-program. Frye MA, Calabrese JR, Reed ML, et al. Use of health care services among persons who screen positive for bipolar disorder. Psychiatr Serv . 2005;56(12):1529-1533. Accessed January 31, 2025. Jain A, Mitra P. Bipolar Affective Disorder. In StatPearls. Treasure Island (FL): StatPearls Publishing; 2021. Judd LL, Schettler PJ, Akiskal HS, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J of Neuropsychopharmacol . 2003;6:127-137. Accessed January 31, 2025. Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord . 2007;9:531-535. Accessed January 31, 2025. Living Well with Bipolar Disorder. Substance Abuse and Mental Health Services Administration. April 28, 2022. Accessed January 31, 2025. https://www.samhsa.gov/serious-mental-illness/bi-polar. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12‑month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry . 2007;64(5):543-552. Accessed January 31, 2025. Miller S, Dell'Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord . 2014;169 Suppl 1:S3‑S11. Accessed January 31, 2025. Seppälä E. Social Connection Boosts Health, Even When You're Isolated. Psychology Today. March 23, 2020. Accessed January 31, 2025. https://www.psychologytoday.com/us/ blog /feeling-it/202003/social-connection-boosts-health-even-when-youre-isolated. State population by characteristics: 2010-2020. United States Census Bureau. October 8, 2021. Accessed January 31, 2025. https://www.census.gov/programs-surveys/popest/technical-documentation/research/evaluation-estimates/2020-evaluation-estimates/2010s-state-detail.html. Tondo L, Vázquez GH, Baldessarini RJ. Depression and Mania in Bipolar Disorder. Curr Neuropharmacol . 2017;15(3):353-358. Accessed January 31, 2025. Terms of Use Privacy Policy Cookie Policy Contact Us References ITCI Corporate Site Sitemap Your Privacy Choices AdChoices Opt-Out © Johnson & Johnson and its affiliates 2025. CAPLYTA and LET IN THE LYTE are trademarks of Johnson & Johnson and its affiliates. Trademarks listed are the property of their respective owners. 11/25 US-CAP-2500312